Objective. The objetive of this study was to evaluate current practice characteristics, treatment choices, clinical experiences, and economic concerns associated with intrathecal therapy.
Introduction
I ntrathecal (IT) drug administration is an effective and widely accepted treatment option for patients who fail to receive adequate pain relief from less invasive methods. Despite recent additions to the published literature, many of the decisions faced in clinical practice are not adequately addressed by the available evidence-based scientific research. Practitioner survey results can identify gaps in the literature and also allow clinicians to compare their own practice choices with those of the broader community.
A survey to assess pain practitioners' IT practices was developed to coincide with the 2007 Polyanalgesic Consensus Conference (PACC). The survey was modeled, in part, on a survey performed in conjunction with the 2000 PACC [1] . The effects of public, private, and workers' compensation insurance on IT treatment were also assessed. It is hoped that the results of this survey will reflect current clinical practice and help identify gaps in the literature that can be bridged with future research.
Methods
The current survey was authored by the program chairs of the 2007 PACC. The authors of the 2007 PACC survey reviewed and updated the 2000 PACC survey in order to assess current IT treatment practices and economic considerations. The focus of the survey conducted in 2000 was on the use of IT therapy in clinical practice, whereas the focus of the current survey was on the evolving challenges in IT therapy, specifically reimbursement. After development, the 2007 PACC survey was reviewed by five independent physicians and five laypeople for clarity and ease of understanding.
Physicians and other health care professionals in the United States who were known to actively use IT therapy in their practices were recruited for participation in the survey. Contact information was obtained via Internet searches, university Websites, association memberships, industry databases, and personal contacts. All 397 eligible practitioners were contacted via e-mail and were provided with the Website address of the survey. The target number of participants was 75, based on the response rate of the 2000 PACC survey and on research into typical response rates of other Web-based physician surveys [2] [3] [4] . Participants were offered a US$25 gift certificate as compensation for their time.
Survey questions, which were predominantly multiple-choice items, appeared consecutively on-screen. The answers were categorical in nature, and the results were summarized descriptively.
Results

Respondent Characteristics
Of the original 397 e-mails sent to eligible practitioners, 68 were returned as undeliverable. Eighty-seven of the remaining 329 practitioners participated, for an overall response rate of 26.4%.
Most participants specialized in anesthesiology (77.0%, N = 67 of 87), worked in a private practice or private hospital (74.7%, N = 65), and had been practicing pain management for more than 10 years (64.4%, N = 56) ( Table 1 ). The majority of participants implanted 25 or fewer pumps (73.3%, N = 63 of 86) per year, and when asked how many pumps they refilled or managed each year, 26.2% (N = 22 of 84) indicated 51-100 and 15.5% (N = 13, each) selected 1-25, 26-50, and 101-150.
Clinical Questions
Neuropathic Pain and IT Drug Use Almost 40% of practitioners indicated that the majority of their patients experience neuropathic pain (Table 2 ). When asked whether neuropathic 
Pump Refills
Approximately one-third of practitioners (34.5%, N = 29 of 84) refill their patients' pumps less frequently than they did 3 years ago; 46.4% (N = 39) indicated that the refill frequency has not changed, and 17.9% (N = 15) refill pumps more frequently (one respondent [1.2%] did not manage pump refills). When the respondents were asked what concentration of morphine they used if they refilled their patients' pumps less frequently, 6.0% (N = 5 of 84) used 10 mg/mL, 36.9% (N = 31) used 20 mg/mL, 25.0% (N = 21) used 30 mg/mL, 3.6% (N = 3) used 40 mg/mL, and 28.6% (N = 24) used 50 mg/mL.
Selecting a Compounding Pharmacy
Only a minority of practitioners (8.3%, N = 7 of 84) did not use a compounding pharmacy. Of the remainder who used a compounding pharmacy, 67.5% (N = 52 of 77) considered reputation for safety to be the most important criterion when selecting a compounding pharmacy; 20.8% (N = 16) indicated that reliable on-time delivery was most important, and drug cost and the ability to bill under assignment of benefit with commercial payers were each considered most important by 5.2% of practitioners (N = 4). One practitioner (1.3%) chose "Other."
Granuloma Formation
Fifty-three practitioners (63.9% of 83 respondents) had treated at least one patient who developed a granuloma ( Figure 1 ). Of these 53 practitioners, 20.8% (N = 11; respondents could choose more than one answer) had an affected patient who developed permanent neurological injury, 45.3% (N = 24) had an affected patient who developed transient neurological injury, and 47.2% (N = 25) had an affected patient who did not develop any type of neurological injury. When asked what methods were used to confirm granuloma formation, 94.3% of practitioners (N = 50 of 53; respondents could choose more than one answer) had used magnetic resonance imaging, 43.4% (N = 23) had obtained a computed tomography (CT)-myelogram, 7.5% (N = 4) had used CT, and 18.9% (N = 10) had performed a sideport study. The most commonly reported methods for managing a granuloma were consultation with a neurosurgeon for granuloma removal (26.4%, N = 14 of 53 respondents), and catheter removal and replacement (24.5%, N = 13) ( Table 3) . None of the respondents reported having been involved in litigation because of a granuloma; however, one respondent reported a pending lawsuit. 
Economic Questions
Economic Considerations in IT Therapy Most practitioners indicated that they were very involved (54.7%, 47 of 86 respondents) or somewhat involved (
Reimbursement for IT Therapy
Most practitioners (83.1%, N = 69 of 83) receive reimbursement from workers' compensation for Յ25% of their pain management patients, and 67.5% (N = 56) indicated that Յ50% of their patients are covered by private insurance (Table 4) . Nearly half of practitioners (47.7%, N = 41 of 86) indicated that most workers' compensation plans and private insurance companies require prior authorizations for IT administered drugs; 45.3% (N = 39) indicated that some plans require prior authorizations, and 7.0% (N = 6) reported that prior authorizations are not required by workers' compensation or private insurers. The majority of practitioners (51.2%, N = 44 of 86) did not know how often they renegotiate contracts with workers' compensation plans and private insurers. Of the remainder, 59.5% (N = 25 of 42) renegotiate every 13 to 24 months, and 40.5% (N = 17) renegotiate every 7 to 12 months. When asked whether they were satisfied with the level of reimbursement received from workers' compensation for IT therapy, four practitioners chose "N/A." Of the remainder, 45.6% (N = 36 of 79) were unsatisfied, 36.7% (N = 29) were satisfied, and 17.7% (N = 14) were unsure. When asked whether they were satisfied with the level of reimbursement received from private insurers for IT therapy, 55.4% of practitioners (N = 46 of 83) were unsatisfied, 25.3% (N = 21) were satisfied, and 19.3% (N = 16) were unsure.
More than 90% of practitioners (N = 76 of 84) believed that their practices were not adequately reimbursed for costs associated with filling, refilling, and programming patient pumps. When asked how often they bill for evaluation and management if these services are performed during a pump refill, 28.6% of practitioners (N = 24 of 84) responded "All of the time," 13.1% (N = 11) indicated "Most of the time," 40.5% (N = 34) selected "Sometimes," and 17.9% (N = 15) chose "Never." Most respondents (63.1%, N = 53 of 84) indicated that the cost of the refill kit was included in the decision for total cost reimbursement; 25.0% (N = 21) indicated that the cost of the refill kit did not enter into the decision, and 11.9% (N = 10) did not know.
The majority (64.0%) of practitioners (N = 55 of 86) indicated that between 26% and 50% of their pain management patients are insured by government payers such as Medicare (Table 4) 
Discussion
The results displayed here and those from a survey published in 2000 [1] suggest that morphine remains the drug of choice for initiation of IT therapy. Physicians who responded to the 2000 survey indicated that 87% of their patients received morphine alone during a trial of IT therapy, and 80.7% of respondents to the current survey choose morphine over other opioid analgesics for initiation of IT therapy. The 2000 survey also revealed that a smaller proportion of physicians would initiate IT therapy with morphine alone for a patient with neuropathic pain (72%) than for a patient with somatic nociceptive pain (87%), suggesting that physicians were less confident about the effectiveness of morphine for neuropathic pain than for other pain syndromes. In the current survey, 80.7% of practitioners believed that opioids were ineffective, or only sometimes effective, for treatment of neuropathic pain. More than 80% of practitioners who responded to the current survey had used ziconotide, a non-opioid IT analgesic, in their practices. Ziconotide is recommended as a first-line therapy in the 2007 PACC algorithm for IT drug selection [5] . The 2007 PACC also reviewed several experimental IT medications, some of which show promise for the treatment of neuropathic pain [6] . Granulomas are a rare but potentially devastating complication associated with IT therapy. Most practitioners in the current survey (63.9%) had treated at least one patient who developed a granuloma; among these practitioners, 66.0% had a patient who experienced neurological injury due to a granuloma. The circumstances that lead to granuloma formation are not well understood, but delivery of high doses or concentrations of opioids may increase patient risk [7] [8] [9] . Notably, more than half of practitioners (57.1%) have prescribed morphine in concentrations that exceed the maximum concentration recommended by the 2007 PACC (20 mg/mL) [5] . An expert panel from the 2007 PACC has published guidelines for the prevention and management of granulomas [10] .
Responses to the series of economic questions reveal that practitioner concerns about cost and reimbursement issues influence treatment choices and practices. Most respondents (87.2%) considered drug cost to be an important or somewhat important consideration when prescribing an IT analgesic. The majority of practitioners (72.1%) indicated that reimbursement rates for IT drugs had decreased over the past 5 years, and a similar proportion (71.1%) expects drug reimbursement to worsen in the future. In addition, more than 90% of respondents believed that reimbursement rates do not adequately cover the cost of filling, refilling, and programming patient pumps. Such economic considerations appear to be negatively affecting the use of IT therapy, with 56.6% of respondents using fewer pumps in their practices because of reimbursement issues.
Although the results of this survey provide insight into the challenges of IT therapy, analyses that included demographic considerations were limited because of the uneven distribution of these parameters. For example, most respondents (77.0%) specialized in anesthesiology and most (70.1%) were in private practice. In future surveys, the role of demographic parameters on practice choices should be considered. Such analyses may provide a better understanding of the current use of IT therapy.
Conclusions
Considerable progress has been made in the field of IT therapy since the 2000 PACC survey. Ziconotide was approved by the United States Food and Drug Administration in 2004, making it the first new IT analgesic in more than a decade to gain such approval. IT drug selection algorithms developed by the 2000 and 2003 PACCs have aided physicians in choosing the safest and most effective drugs for their patients, a trend that has continued with the publication of the 2007 PACC algorithm [5] . Strides have also been made in the prevention and treatment of granulomas. Despite these and other advances, results of the current survey suggest that economic and reimbursement difficulties are limiting the use of IT therapy. Considering the current economic environment, reimbursement issues will likely continue to be a challenge for clinicians and patients. Additional studies are needed to further evaluate the effects of economic trends on patient access to this valuable treatment modality.
